News

Hims & Hers Stock Tumbles as Novo Nordisk Ends Its Wegovy Sales Deal. Can the Telehealth Giant Recover?
The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.
Health Rounds: Novo Nordisk's semaglutide may help some with type 1 diabetes
People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...
Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
Novo Nordisk Stock Drops on Weight-Loss Data. Why Investors Have Doubts.
Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...
Novo Seeks Deals to Reverse Slide in Weight-Loss Market It Made
Novo Nordisk A/S is hunting for more early-stage deals to pad its pipeline of next-generation obesity drugs, as the drugmaker ...
Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints
Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...
Experimental drug helps patients lose nearly a quarter of body weight in early trials
Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...
STAT6d
Full data on Novo Nordisk’s new amylin drug raise dosing questions
Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, ...